Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$221.64 -3.6%	$238.45	$96.09 ▼ $260.19	$11.84B	0.6	1.21 million shs	776,378 shs
DYN Dyne Therapeutics	$23.45 -1.2%	$19.92	$8.88 ▼ $25.00	$3.92B	1.06	2.13 million shs	2.53 million shs
ELAN Elanco Animal Health	$25.18 -2.5%	$23.70	$13.39 ▼ $27.72	$12.90B	1.68	4.05 million shs	3.67 million shs
SMMT Summit Therapeutics	$13.50 -2.2%	$15.32	$12.55 ▼ $30.98	$10.72B	-1.26	4.07 million shs	2.70 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-3.63%	-2.91%	-11.52%	+21.13%	+98.42%
DYN Dyne Therapeutics	-1.22%	-0.80%	+18.43%	+22.07%	+159.98%
ELAN Elanco Animal Health	-2.58%	+0.20%	+3.99%	+11.16%	+70.33%
SMMT Summit Therapeutics	-2.24%	-11.76%	-1.82%	-48.82%	-48.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$221.64 -3.6%	$238.45	$96.09 ▼ $260.19	$11.84B	0.6	1.21 million shs	776,378 shs
DYN Dyne Therapeutics	$23.45 -1.2%	$19.92	$8.88 ▼ $25.00	$3.92B	1.06	2.13 million shs	2.53 million shs
ELAN Elanco Animal Health	$25.18 -2.5%	$23.70	$13.39 ▼ $27.72	$12.90B	1.68	4.05 million shs	3.67 million shs
SMMT Summit Therapeutics	$13.50 -2.2%	$15.32	$12.55 ▼ $30.98	$10.72B	-1.26	4.07 million shs	2.70 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-3.63%	-2.91%	-11.52%	+21.13%	+98.42%
DYN Dyne Therapeutics	-1.22%	-0.80%	+18.43%	+22.07%	+159.98%
ELAN Elanco Animal Health	-2.58%	+0.20%	+3.99%	+11.16%	+70.33%
SMMT Summit Therapeutics	-2.24%	-11.76%	-1.82%	-48.82%	-48.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.95	Moderate Buy	$261.48	17.97% Upside
DYN Dyne Therapeutics	2.86	Moderate Buy	$34.17	45.70% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$28.55	13.39% Upside
SMMT Summit Therapeutics	2.44	Hold	$26.97	99.80% Upside

Current Analyst Ratings Breakdown

Latest DYN, ELAN, AXSM, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$310.00
7/17/2026	AXSM Axsome Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DYN Dyne Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/15/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
7/8/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
7/7/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$302.00 ➝ $304.00
6/29/2026	ELAN Elanco Animal Health	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/26/2026	DYN Dyne Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
6/18/2026	ELAN Elanco Animal Health	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
6/17/2026	AXSM Axsome Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$275.00 ➝ $300.00

(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	17.86	N/A	N/A	$1.75 per share	126.65
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
ELAN Elanco Animal Health	$4.72B	2.67	$2.26 per share	11.13	$13.18 per share	1.91
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	54.59	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.22	N/A	N/A	N/A	N/A	-58.28%	-46.77%	7/27/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	20.30	1.69	-4.95%	7.42%	3.66%	8/5/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.60	N/A	N/A	N/A	N/A	-291.24%	-243.07%	7/23/2026 (Estimated)

Latest DYN, ELAN, AXSM, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8919	N/A	N/A	N/A	$221.21 million	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.27	N/A	N/A	N/A	$1.31 billion	N/A
7/27/2026	Q2 2026	DYN Dyne Therapeutics	-$0.74	N/A	N/A	N/A	N/A	N/A
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.26	N/A	N/A	N/A	$0.11 million	N/A
5/11/2026	Q1 2026	DYN Dyne Therapeutics	-$0.7723	-$0.73	+$0.0423	-$0.73	N/A	N/A
5/6/2026	Q1 2026	ELAN Elanco Animal Health	$0.34	$0.40	+$0.06	$0.11	$1.28 billion	$1.37 billion
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million
5/1/2026	Q1 2026	SMMT Summit Therapeutics	-$0.2692	-$0.24	+$0.0292	-$0.24	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	2.27	1.39	1.32
DYN Dyne Therapeutics	0.17	19.92	19.92
ELAN Elanco Animal Health	0.60	2.16	1.12
SMMT Summit Therapeutics	N/A	7.41	7.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
DYN Dyne Therapeutics	96.68%
ELAN Elanco Animal Health	97.48%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
DYN Dyne Therapeutics	9.46%
ELAN Elanco Animal Health	1.14%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
DYN Dyne Therapeutics	100	165.31 million	149.68 million	Optionable
ELAN Elanco Animal Health	9,400	499.45 million	493.76 million	Optionable
SMMT Summit Therapeutics	110	776.16 million	128.07 million	Optionable

DYN, ELAN, AXSM, and SMMT Headlines

Recent News About These Companies

Summit Therapeutics (SMMT) Expected to Announce Quarterly Earnings on Thursday

July 19 at 2:10 AM | americanbankingnews.com

Summit Therapeutics (SMMT) Projected to Post Earnings on Thursday

July 19 at 2:10 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Downgraded by Wall Street Zen to "Sell"

July 18 at 1:35 AM | marketbeat.com

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

July 17, 2026 | globenewswire.com

Summit Therapeutics (NASDAQ:SMMT) Share Price Crosses Below 50-Day Moving Average - What's Next?

July 17, 2026 | marketbeat.com

Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal

July 15, 2026 | zacks.com

119,655 Shares in Summit Therapeutics PLC $SMMT Bought by Y Intercept Hong Kong Ltd

July 9, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Hold" by Brokerages

July 9, 2026 | marketbeat.com

SMMT Stock Price Prediction

July 4, 2026 | 247wallst.com

Hsbc Holdings PLC Buys New Shares in Summit Therapeutics PLC $SMMT

July 1, 2026 | marketbeat.com

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet

June 22, 2026 | seekingalpha.com

Summit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 3,810,000 Shares

June 13, 2026 | insidertrades.com

Why is SMMT stock tumbling today?

June 10, 2026 | msn.com

Summit Therapeutics Announces Proposed Public Offering of Common Stock

June 9, 2026 | businesswire.com

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

June 7, 2026 | 247wallst.com

The Era of the One-Size-Fits-All Cancer Drug Is Ending

June 6, 2026 | wsj.com

Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data

June 5, 2026 | finance.yahoo.com

Summit Therapeutics (NASDAQ:SMMT) CFO Manmeet Singh Soni Buys 50,000 Shares

June 5, 2026 | insidertrades.com

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

June 4, 2026 | businesswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)

June 4, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DYN, ELAN, AXSM, and SMMT Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$221.64 -8.36 (-3.63%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$226.08 +4.44 (+2.00%)

As of 07/20/2026 07:45 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Dyne Therapeutics NASDAQ:DYN

$23.45 -0.29 (-1.22%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$23.92 +0.48 (+2.03%)

As of 07/20/2026 07:40 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Elanco Animal Health NYSE:ELAN

$25.18 -0.66 (-2.54%)

Closing price 07/20/2026 03:59 PM Eastern

Extended Trading

$25.50 +0.33 (+1.30%)

As of 07/20/2026 07:56 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Summit Therapeutics NASDAQ:SMMT

$13.50 -0.31 (-2.24%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$13.61 +0.11 (+0.84%)

As of 07/20/2026 07:55 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, ELAN, AXSM, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, ELAN, AXSM, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, ELAN, AXSM, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, ELAN, AXSM, and SMMT Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Dyne Therapeutics NASDAQ:DYN

Elanco Animal Health NYSE:ELAN

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, ELAN, AXSM, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, ELAN, AXSM, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, ELAN, AXSM, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, ELAN, AXSM, and SMMT Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Dyne Therapeutics NASDAQ:DYN

Elanco Animal Health NYSE:ELAN

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools